Amgen stock holds near 52-week high after earnings beat and insider sale

Amgen Inc. (US0311621009) stock is trading close to its recent 52-week high as of August 13, 2026, after the biotechnology company delivered an earnings beat and updated full-year 2026 guidance while an insider share sale drew attention to its strong run.

Earnings beat and fresh 2026 guidance

Per a detailed earnings summary reported on August 14, 2026, Amgen posted non-GAAP earnings per share of $6.29 for its latest quarter, exceeding analysts' consensus estimates of $5.62 by $0.67 and marking an increase from $6.02 in the same quarter a year earlier. This overview also notes that management has set full-year 2026 EPS guidance in a range of $22.300 to $23.500, while sell-side forecasts cluster around $22.78 for the current year.

The earnings surprise is material: the $0.67 EPS beat versus consensus for the quarter, combined with the upwardly framed full-year EPS range, signals that Amgen's operational performance is running ahead of prior expectations rather than simply in line with them. With the prior-year quarter generating $6.02 per share, the latest print shows earnings per share growing by $0.27 year over year, even as the company invests in its pipeline and absorbs the costs of recent product launches.

Insider sale underscores share price strength

The same August 14, 2026 coverage highlights an insider transaction in which a senior vice president at Amgen sold shares valued at $521,370.36, a move that came as the stock traded close to its 52-week high and that was disclosed in a recent regulatory filing. The report points out that Amgen shares were up 0.4% to $417.84, just below the 52-week high of $421.79, during midday trading on August 13, 2026.

For investors, the context matters: a realized sale of $521,370.36 at a share price of $417.84 does not necessarily signal weakening confidence, but it does highlight how far the stock has climbed relative to its own recent history. With the 52-week high standing at $421.79, the $417.84 print leaves the stock only $3.95 below that level, underscoring that the market is pricing Amgen close to the upper end of its one-year trading range as it digests the latest earnings and guidance.

Valuation, consensus targets and recent performance

The same August 14, 2026 data set indicates that the consensus target price on Amgen stock currently sits at $371.68, below the actual trading level of $417.84, implying that the stock is trading at a premium to the average analyst valuation snapshot. This consensus view is paired with an average rating of Hold, suggesting that, at least on paper, analysts see limited upside from current levels even after the quarterly beat and raised full-year guidance.

Market data compiled on August 14, 2026 shows Amgen stock changing hands at $417.84 with a market capitalization of $248.18 billion, a price-to-earnings ratio of 25.85 and a dividend yield of 2.35%. The same quote snapshot notes that on August 13, 2026, the stock traded between a low of $415.83 and a high of $420.26, placing the closing level 0.5% above the intraday low and 0.6% below the intraday high on that session.

This recent performance sits within a broader price trend captured on August 14, 2026, where Amgen closed at $417.990, up $1.810 or 0.43%, at 4:00 p.m. ET on August 13, 2026. The TradingKey market trends page and a complementary technical overview underline that shares have gained 3.21% over the past five trading days and 27.66% since the start of the year, with the latest technical signal described as Neutral rather than strongly bullish or bearish.

Operational backdrop and revenue trajectory

Beyond the earnings per share figures, Amgen's latest revenue trajectory provides additional context for the stock's valuation. A fundamental analysis published on August 14, 2026 notes that Amgen recently reported revenue growth of 12%, driven by double-digit growth from 16 products, while non-GAAP EPS increased by 1% because higher operating expenses and a higher tax rate offset part of the top-line momentum. This overview also indicates that management slightly raised its 2025 top-line and bottom-line guidance, reflecting confidence in the durability of its product portfolio.

Because that revenue-growth snapshot is tied to guidance for 2025 and an earlier reporting period, it functions as historical context rather than a direct read on Amgen's latest quarter. Even so, a 12% revenue increase and a 1% non-GAAP EPS rise, paired with guidance that has been nudged higher, help explain why the market has been willing to assign a P/E multiple of 25.85 and to keep the shares close to their 52-week high following the more recent earnings beat and full-year 2026 EPS range.

Product focus - key therapies underpinning growth

Amgen's ability to deliver EPS of $6.29 in the latest quarter and to outline full-year 2026 EPS guidance between $22.300 and $23.500 is underpinned by a broad portfolio of biologic and specialty therapies, including flagship products in oncology, inflammation and other serious disease areas. Across 16 products showing double-digit revenue growth in the most recently highlighted period, the company is leveraging established brands and newer launches to sustain its top-line expansion, which in turn supports the confidence embedded in the 2025 and 2026 guidance ranges referenced in recent analyses.

For retail investors, the core narrative around Amgen's products is that a diversified mix of therapies reduces reliance on a single franchise and allows the company to absorb competition and patent expirations while continuing to invest in innovation. The revenue growth spread across multiple products, as cited in recent fundamental coverage, suggests that the earnings beat in the latest quarter is not solely a cost-management story but is linked to underlying demand for the company's medicines, a factor that helps justify the current valuation even as the share price runs ahead of consensus targets.

Amgen stock price level and trading context

As of the close on August 13, 2026, Amgen stock finished regular Nasdaq trading at $417.99, up $1.81 or 0.43% on the day, with quotes delayed by 15 minutes on the referenced market-data page. This company snapshot reinforces the picture of a large-cap biotechnology stock that is trading close to its 52-week high of $421.79 and within a daily range of $415.83 to $420.26 as captured in the August 13, 2026 session.

With a market capitalization of $248.18 billion as of August 13, 2026 and a dividend yield of 2.35%, Amgen combines income characteristics with growth exposure. The share price of $417.84 to $417.99 as reported in the various quote snapshots stands well above the consensus target price of $371.68, illustrating a gap of more than $46 between where the market is currently trading the stock and where the average analyst valuation places it. That differential, in combination with the recent earnings beat and the EPS guidance range of $22.300 to $23.500, gives investors a concrete basis to weigh whether the premium valuation is warranted.

Read more

Further details on Amgen's investor communications, including full financial statements, strategic updates and pipeline disclosures, are available on its dedicated investor relations site. The investor relations portal provides access to quarterly reports, earnings call materials and presentations that elaborate on the revenue growth from 16 products, updated guidance for 2025 and 2026, and the broader strategy behind its capital allocation and R&D investments.

Representative therapy driving demand

A representative example of the type of product that supports Amgen's earnings trajectory is one of its leading biologic therapies used in the treatment of serious inflammatory conditions. This category of medicine is designed to modulate the immune system and has contributed to the double-digit growth figures mentioned in recent fundamental commentary, illustrating how demand for innovative treatments can translate into sustained revenue streams.

Such therapies typically carry complex manufacturing requirements and are sold primarily to hospitals and specialist clinics, which means they benefit from barriers to entry and established prescriber relationships. For investors, understanding how a flagship biologic fits into Amgen's broader portfolio helps contextualize the $6.29 quarterly EPS figure and the full-year 2026 EPS guidance range, both of which rest on the continued commercial success of advanced treatments in multiple indications.

Shares at high end of range

Amgen stock currently trades on the Nasdaq exchange, with the closing price of $417.99 on August 13, 2026 placing it close to the high end of its recent trading range and only a few dollars below its 52-week peak of $421.79. In light of the company’s market capitalization of $248.18 billion and its dividend yield of 2.35%, the shares offer a mix of income and growth characteristics that investors can evaluate against the valuation metrics highlighted in recent market data.

As of the August 13, 2026 close, Amgen shares are near their 52-week high, supported by an earnings per share beat of $0.67 versus consensus in the latest quarter, a year-over-year EPS increase from $6.02 to $6.29, and full-year 2026 EPS guidance between $22.300 and $23.500, even as the consensus target price of $371.68 sits below the current trading level.

Fact box

Company: Amgen Inc.

ISIN: US0311621009

Ticker: AMGN

Exchange: Nasdaq

Price (as of August 13, 2026, 4:00 p.m. ET): $417.99 USD

Market cap: $248.18 billion (as of August 13, 2026)

Sector / Industry: Biotechnology / Pharmaceuticals

Index membership: S&P 500